Nasdaq

Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of ...
TCTMD

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

ROME, Italy—Andexanet alfa, which recently hit a road block on its path to approval by the US Food and Drug Administration (FDA), induces rapid reversal of the anticoagulant effects of factor Xa ...
Yahoo Finance

Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban

Portola Pharmaceuticals (Nasdaq: PTLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal ...
Medscape

Anticoagulant Reversal Drug Andexxa Voluntarily Pulled From US Market

The anticoagulant reversal drug Andexxa was voluntarily pulled from the US market after failing to secure full FDA approval ...
Yahoo Finance

Portola Announces Its Factor Xa Inhibitor Antidote PRT4445 Produces Rapid, Sustained and Dose-Related Reversal of the Anticoagulant Activity of Eliquis(R) in Phase 2 Study

SOUTH SAN FRANCISCO, CA--(Marketwired - May 8, 2013) - Portola Pharmaceuticals, Inc. today announced efficacy and safety data from the Phase 2 proof-of-concept study of PRT4445 in healthy volunteers ...
TCTMD

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

The US Food and Drug Administration (FDA) has cleared andexanet alfa (Andexxa) as a reversal agent for the anticoagulant effects of the two most commonly used factor Xa inhibitors in patients with ...
Healio

AIMS65 ‘reliable predictor’ of death, rebleeding after factor Xa reversal for GI bleeding

Please provide your email address to receive an email when new articles are posted on . AIMS65 score predicted mortality and rebleeding for patients on anticoagulants with gastrointestinal bleeding.
Healio

ANNEXA-4: Reversal agent effective in patients with acute major bleeding after Factor Xa inhibitor use

Andexanet alfa, a novel reversal agent, was effective at stopping acute major bleeding in patients taking Factor Xa inhibitors, according to results from the ANNEXA-4 study. Stuart J. Connolly, MD, ...
Monthly Prescribing Reference

BLA Accepted for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy

CSL Behring announced that the FDA has accepted for standard review its Biologics License Application (BLA) for a human 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of ...
Medscape

More Hope for Factor Xa Reversal

February 10, 2012 (Tokyo, Japan) —Another study has suggested that the anticoagulant effects of the new factor Xa inhibitors could be reversed by several hemostatic agents currently used to control ...
PharmiWeb

Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of ...